Neurol. praxi. 2025;26(3):185-191 | DOI: 10.36290/neu.2025.018

Continuous immunomodulation and immunosuppression versus reconstitution therapy in multiple sclerosis

doc. MUDr. Ema Kantorová, PhD.
Neurologická klinika, Univerzita Komenského v Bratislave, Jesseniova lekárska fakulta v Martine, Univerzitná nemocnica Martin

Multiple sclerosis (MS) is a common immune-mediated demyelinating and degenerative disease of the central nervous system (CNS), which can lead to serious disability early in its course. The expanding portfolio of therapeutic agents against MS reflects progress in our understanding of MS pathogenesis and the mechanisms of CNS injury. Early initiation of treatment is recommended. Moderate-efficacy or high-efficacy immunotherapeutics can be used. The escalation strategy involves gradually increasing the intensity of treatment, while the induction strategy supports initiating treatment with highly effective therapeutics. Both continuous immunomodulation/immunosuppression and pulsed immune reconstitution treatments are available. In this review, we describe current treatment strategies and compare the advantages and disadvantages of continuous immunomodulation, immunosuppression, and immune reconstitution therapy.

Keywords: multiple sclerosis, treatment, escalation, induction, immunosuppression, immune reconstitution.

Received: February 3, 2025; Revised: March 2, 2025; Accepted: March 6, 2025; Prepublished online: March 6, 2025; Published: July 4, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kantorová E. Continuous immunomodulation and immunosuppression versus reconstitution therapy in multiple sclerosis. Neurol. praxi. 2025;26(3):185-191. doi: 10.36290/neu.2025.018.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 4.7.2026

    References

    1. . AlSharoqi IA, Aljumah M, Bohlega S, et al. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. Neurol Ther. 2020;9(1):55-66. Go to original source... Go to PubMed...
    2. . Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis. The MIRROR study. Neurology. 2018;90(20):e1805-e1814. Go to original source... Go to PubMed...
    3. . Brod SA. The genealogy, methodology, similarities, and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica. Autoimmun Rev. 2022;21(10):103170. Go to original source... Go to PubMed...
    4. . CAMMS223 Trial Investigators, Coles AJ, Compston DAS, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786-801.
    5. . Clerico M, Artusi CA, Di Liberto A, et al. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis. Expert Opin Drug Saf. 2017;16:963-72. Go to original source... Go to PubMed...
    6. . Cohen JA, Coles AJ, Arnold DL et al. Alemtuzumab vs. interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819-1828. Go to original source... Go to PubMed...
    7. . Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017;89(11):1117-1126. Go to original source... Go to PubMed...
    8. . Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet. 2012;380(9856):1829-1839. Go to original source... Go to PubMed...
    9. . Comi G, Cook S, Rammohan K, et al. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. Ther Adv Neurol Disord. 2018;11:175628561775(3365). Go to original source... Go to PubMed...
    10. . Comi G, O'Connor P, Montalban X, et al; FTY720D2201 Study Group. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010;16(2):197-207. Go to original source... Go to PubMed...
    11. . Confavreux C, O'Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247-56. doi:10.1016/S1474-4422(13)70308-9. Go to original source... Go to PubMed...
    12. . De Sèze J, Suchet L, Mekies, C. et al. The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus. Neurol Ther. 2023;12:351-369. Go to original source... Go to PubMed...
    13. . Förster M, Graf J, Mares J, et al. Drug treatment of clinically isolated syndrome. CNS Drugs. 2019;33:659-676. Go to original source... Go to PubMed...
    14. . Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416-26. doi:10.1056/NEJMoa0902533. Go to original source... Go to PubMed...
    15. . Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2017;24:1594-604. doi: 10.1177/1352458517727603. Go to original source... Go to PubMed...
    16. . Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76:536-541. Go to original source... Go to PubMed...
    17. . Hauser SL, Bar-Or A, Cohen JA, et al. ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557. Go to original source... Go to PubMed...
    18. . Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221-34. doi: 10.1056/NEJMoa1601277. Go to original source... Go to PubMed...
    19. . Havrdova E, Douglas DL, Cohen JA, et al. Alemtuzumab CARE-MS I 5-year follow-up. Durable efficacy in the absence of continuous MS therapy. Neurology. 2017;89(11):1107-1116. Go to original source... Go to PubMed...
    20. . Heckova E, Dal-Bianco A, Strasser B, et al. Extensive Brain Pathologic Alterations Detected with 7.0-T MR Spectroscopic Imaging Associated with Disability in Multiple Sclerosis. Radiology. 2022;303(1):141-150. doi: 10.1148/radiol.210614. Go to original source... Go to PubMed...
    21. . Ingwersen J, Aktas O, Hartung HP. Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics. 2016;13(1):47-57. Go to original source... Go to PubMed...
    22. . Kappos L, Antel J, Comi G, et al; FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124-1140. Go to original source... Go to PubMed...
    23. . Kappos L, Bar-Or A, Cree BAC, et al. EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Go to original source... Go to PubMed...
    24. . Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol. 2021;78:558-567. Go to original source... Go to PubMed...
    25. . Kappos L, Radue EW, O'Connor P, et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New Engl J Med. 2010;362(5):387-401. Go to original source... Go to PubMed...
    26. . Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77:1132-1140. Go to original source... Go to PubMed...
    27. . Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler. 2017;23:1233-1240. Go to original source... Go to PubMed...
    28. . Leist TP, Comi G, Cree BAC, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLEMS): a phase 3 randomised trial. Lancet Neurol. 2014;13:257-67. Go to original source... Go to PubMed...
    29. . Lisý Ľ. Individualizácia pacienta pri výbere vhodnej liečby sclerosis multiplex. Via pract. 2016; 13(5):191-194.
    30. . Lünemann JD, Ruck T, Muraro PA, et al. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol. 2020;16(1):56-62. doi: 10.1038/s41582-019-0268-z. Go to original source... Go to PubMed...
    31. . Mallucci G, Annovazzi P, Miante S, et al. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. J Neurol. 2018;265:1850-9. Go to original source... Go to PubMed...
    32. . McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016;87:117-25.
    33. . Miclea A, Leussink VI, Hartung HP, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. J Neurol. 2016;263:1626-32. Go to original source... Go to PubMed...
    34. . Minneboo A, Barkhof F, Polman CH, Uitdehaag BM, Knol DL, Castelijns JA. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol. 2004;61(2):217-221. Go to original source... Go to PubMed...
    35. . Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209-20. doi: 10.1056/NEJMoa1 606468. Go to original source... Go to PubMed...
    36. . Newsome S, Krzystanek E, Selmaj K, et al. Subcutaneous ocrelizumab in patients with multiple sclerosis: results of the phase III OCARINA II study. J Neurol Neurosurg Psychiatry. 2024;95:A14. Go to original source...
    37. . O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293-303. doi: 10.1056/NEJMoa1014656. Go to original source... Go to PubMed...
    38. . Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354:899-910. Go to original source... Go to PubMed...
    39. . Rommer PS, Milo R, Han MH, et al. Immunological Aspects of Approved MS Therapeutics. Front Immunol. 2019;10:1564. doi: 10.3389/fimmu.2019.01564. Go to original source... Go to PubMed...
    40. . Ruggieri S, Quartuccio ME, Prosperini L. Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data. Degener Neurol Neuromuscul Dis. 2022;12:61-73. Go to original source... Go to PubMed...
    41. . Rudick RA, StuartWH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911-23. doi: 10.1056/NEJMoa044396. Go to original source... Go to PubMed...
    42. . Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015;11:379-389. Go to original source... Go to PubMed...
    43. . Selmaj K, Cree BAC, Barnett M, et al. Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol. 2024;271(1):105-115. doi: 10.1007/s00415-023-11969-8. Go to original source... Go to PubMed...
    44. . Sellner J, Rommer PS. Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review. Autoimmun Rev. 2020;102492. Go to original source... Go to PubMed...
    45. . Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014;82(7):573-81. Go to original source... Go to PubMed...
    46. . Stüve O. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J Neurol Sci. 2008 Nov 15;274(1-2):39-41. doi: 10.1016/j.jns.2008.03.022. Go to original source... Go to PubMed...
    47. . Stüve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006 Oct;63(10):1383-7. doi: 10.1001/archneur.63.10.1383. Go to original source... Go to PubMed...
    48. . Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. Go to original source... Go to PubMed...
    49. . Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: A randomised, controlled phase 3 trial. Mult Scler. 2014;20(6):705-716. Go to original source... Go to PubMed...
    50. . Viglietta V, Miller D, Bar-Or A, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015;2:103-18. doi:10.1002/acn3.148. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.